Market capitalization | $2.64b |
Enterprise Value | $2.08b |
P/E (TTM) P/E ratio | 17.04 |
EV/FCF (TTM) EV/FCF | 9.03 |
EV/Sales (TTM) EV/Sales | 6.53 |
P/S ratio (TTM) P/S ratio | 8.26 |
P/B ratio (TTM) P/B ratio | 4.86 |
Revenue (TTM) Revenue | $319.12m |
EBIT (operating result TTM) EBIT | $152.24m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
7 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
7 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -79 -79 |
38%
38%
|
|
Depreciation and Amortization | 3.31 3.31 |
221%
221%
|
|
Stock Compensation | 29 29 |
21%
21%
|
|
Operating Cash Flow | -70 -70 |
35%
35%
|
|
Investments | 0.61 0.61 |
24%
24%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -71 -71 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Head office | United States |
CEO | Dinesh Patel |
Employees | 112 |
Founded | 2006 |
Website | www.protagonist-inc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.